Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07541287 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy | PHASE2 | RECRUITING | 30 | — | — | May 19, 2026 | Apr 1, 2029 | May 29, 2026 | 7 | United States, New Zealand |
The proportion of participants who experience one or more adverse events that begin or worsen after the first dose of study drug
| Arm | Type | Description |
|---|---|---|
| JADE101 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE101 |
| Name | Type | Description |
|---|---|---|
| JADE101 | DRUG | JADE101 is supplied as sterile solution to be administered by SC injection |
Inclusion Criteria: 1. Male or female participants 18-60 years of age, inclusive, and of local legal consenting age at the time of signing the informed consent 2. eGFR ≥ 30 mL/min/1.73 m2 3. Biopsy-confirmed primary IgAN 4. Receiving stable and maximally tolerated doses of either ACEi or ARB as per...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | BION-1301, LNP023, Atrasentan, Zigakibart, zigakibart |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Travere Therapeutics, Inc. | TVTX | 2 | PHASE3 | sparsentan, irbesartan, Dapagliflozin, Sparsentan |
| Biogen Inc. | BIIB | 1 | PHASE3 | Felzartamab |
| Vertex Pharmaceuticals Incorporated | VRTX | 2 | PHASE3 | Povetacicept |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Biohaven Ltd. | BHVN | 1 | PHASE1 | BHV-1400 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |